When analyzed together to investigate the role of active pharmacological treatment, the ‘T’ allele of rs588765 was associated with increased smoking abstinence during treatment (OR=1.85, Fig.1C&3C). Adjusting for age, sex, baseline CPD, menthol status, type of counseling sessions and type of pharmacological treatment did not meaningfully alter the association between rs588765 and smoking abstinence (OR=1.81, Fig.3C). Among the participants who received the placebo treatment (Fig.1D&3C), the ‘T’ allele of rs588765 was associated with reduced abstinence during treatment (OR=0.49, Fig.1D&3C); adjusting for age, sex, baseline CPD, menthol status, and type of counseling sessions did not meaningfully alter the odds ratio between rs588765 and smoking abstinence during treatment (OR=0.47, Fig.3C). There was also a significant treatment (combined active vs. combined placebo) by rs588765 genotype interaction during treatment (OR=3.75, P<0.001). Rs588765 was not associated with smoking abstinence at end of treatment or at 6-month follow up.
